Ocular Therapeutix (OCUL) closed at $6.60 on November 6, 2026, up 2.6% from the previous close, on volume of 1,849,343 shares (30-day average 3,443,047).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Call Spread | 15-Jan : 19-Mar-27 8 C | 200 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
At a glance: Stocks gapping down premarket
Seeking Alpha News (Mon, 9-Nov 8:51 AM ET)
Ocular Therapeutix Elects Riad Sherif to Board, Director Resigns
TipRanks (Mon, 9-Nov 7:47 AM ET)
Ocular Therapeutix GAAP EPS of -$0.42 misses by $0.06, revenue of $12.88M misses by $1.42M
Seeking Alpha News (Mon, 9-Nov 7:06 AM ET)
Ocular Therapeutix Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sun, 8-Nov 6:04 PM ET)
Ocular Therapeutix Q3 2026 Earnings Preview
Seeking Alpha News (Fri, 6-Nov 7:33 AM ET)
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 7:00 AM ET)
Ocular Therapeutix to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Ocular Therapeutix to Participate in November Investor and Scientific Conferences
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Ocular Therapeutix to Participate in October Scientific and Investor Conferences
Globe Newswire (Thu, 1-Oct 7:00 AM ET)
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix trades on the NASDAQ stock market under the symbol OCUL.
As of November 9, 2026, OCUL stock price climbed to $6.62 with 1,166,787 million shares trading.
OCUL has a beta of 1.48, meaning it tends to be more sensitive to market movements. OCUL has a correlation of 0.08 to the broad based SPY ETF.
OCUL has a market cap of $1.45 billion. This is considered a Small Cap stock.
Last quarter Ocular Therapeutix reported $13 million in Revenue and -$.35 earnings per share. This beat revenue expectation by $379,040 and exceeded earnings estimates by $.04.
In the last 3 years, OCUL traded as high as $16.44 and as low as $2.00.
The top ETF exchange traded funds that OCUL belongs to (by Net Assets): VTI, IWM, VXF, IWO, PJP.
OCUL has underperformed the market in the last year with a return of -37.7%, while the SPY ETF gained +12.9%. In the last 3 month period, OCUL fell short of the market, returning -24.3%, while SPY returned -2.3%. However, in the most recent 2 weeks OCUL has outperformed the stock market by returning +1.8%, while SPY returned -1.4%.
OCUL support price is $6.28 and resistance is $6.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCUL shares will trade within this expected range on the day.
